Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

RegeneRx, G-treeBNT create JV around ophthalmic candidate RGN259

Executive Summary

Teaming up for the second time, RegeneRx Biopharmaceuticals Inc. and G-treeBNT Co. Ltd. (formerly Digital Aria) created a yet-to-be named joint venture that will hold exclusive US rights to the former's Phase II RGN259 for dry eye and the orphan condition neurotrophic keratitis, a degenerative corneal epithelium disease. NOTES: The joint venture is called ReGenTree LLC. RGN259 is also known under other names, including thymosin beta-4, GBT101, GBT201, RGN137 RGN352, and RGN457.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • Joint Venture
    • R&D and Marketing (Licensing)

Related Companies